Publication List
Endothelial ROBO4 suppresses PTGS2/COX-2 expression and inflammatory diseases
Tanaka M., Shirakura K., Takayama Y., Μatsui M., Watanabe Y., Yamamoto T., Takahashi J., Tanaka S., Hino N., Doi T., Obana M., Fujio Y., Takayama K.*, Okada Y.*
Commun Biol. 2024 May 18;7(1):599.
Micro-patterned culture of iPSC-derived alveolar and airway cells distinguishes SARS-CoV-2 variants
Masui A., Hashimoto R., Matsumura Y., Yamamoto T., Nagao M., Noda T., Takayama K.*, Gotoh S.*
Stem Cell Reports. 2024 Apr 9;19(4):545-561.
Longitudinal analysis of genomic mutations in SARS-CoV-2 isolates from persistent COVID-19 patient
Futatsusako H., Hashimoto R., Yamamoto M., Ito J., Matsumura Y., Yoshifuji H., Shirakawa K., Takaori-Kondo A.; Genotype to Phenotype Japan (G2P-Japan) Consortium; Sato K., Nagao M.*, Takayama K.*
iScience. 2024 Mar 29;27(5):109597.
Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant
Tamura T., Irie T., Deguchi S., Yajima H., Tsuda M., Nasser H., Mizuma K., Plianchaisuk A., Suzuki S., Uriu K., Begum MM., Shimizu R., Jonathan M., Suzuki R., Kondo T., Ito H., Kamiyama A., Yoshimatsu K., Shofa M., Hashimoto R., Anraku Y., Kimura KT., Kita S., Sasaki J., Sasaki-Tabata K., Maenaka K., Nao N., Wang L., Oda Y.; Genotype to Phenotype Japan (G2P-Japan) Consortium; Ikeda T., Saito A., Matsuno K., Ito J., Tanaka S., Sato K.*, Hashiguchi T.*, Takayama K.*, Fukuhara T*.
Nat Commun. 2024 Feb 8;15(1):1176.
Virological characteristics of the SARS-CoV-2 BA.2.86 variant
Tamura T., Mizuma K., Nasser H., Deguchi S., Padilla-Blanco M., Oda Y., Uriu K., Tolentino JEM., Tsujino S., Suzuki R., Kojima I., Nao N., Shimizu R., Wang L., Tsuda M., Jonathan M., Kosugi Y., Guo Z., Hinay AA Jr., Putri O., Kim Y., Tanaka YL., Asakura H., Nagashima M., Sadamasu K., Yoshimura K.; Genotype to Phenotype Japan (G2P-Japan) Consortium; Saito A., Ito J., Irie T., Tanaka S., Zahradnik J.*, Ikeda T.*, Takayama K.*, Matsuno K.*, Fukuhara T.*, Sato K.*
Cell Host Microbe. 2024 Feb 14;32(2):170-180.e12.
SARS-CoV-2-induced disruption of a vascular bed in a microphysiological system caused by type-I interferon from bronchial organoids
Fujimoto K., Kameda Y., Nagano Y., Deguchi S., Yamamoto T., Krol RP., Gee P., Matsumura Y., Okamoto T., Nagao M., Takayama K.*, Yokokawa R.*
Lab Chip. 2024 Jan 22. doi: 10.1039/d3lc00768e. Epub ahead of print.
Complement factor D targeting protects endotheliopathy in organoid and monkey models of COVID-19
Kawakami E., Saiki N., Yoneyama Y., Moriya C., Maezawa M., Kawamura S., Kinebuchi A., Kono T., Funata M., Sakoda A., Kondo S., Ebihara T., Matsumoto H., Togami Y., Ogura H., Sugihara F., Okuzaki D., Kojima T., Deguchi S., Vallee S., McQuade S., Islam R., Natarajan M., Ishigaki H., Nakayama M., Nguyen CT., Kitagawa Y., Wu Y., Mori K., Hishiki T., Takasaki T., Itoh Y., Takayama K., Nio Y., Takebe T.
Cell Stem Cell. 2023 Oct 5;30(10):1315-1330.e10.
Multiple mutations of SARS-CoV-2 Omicron BA.2 variant orchestrate its virological characteristics
Kimura I., Yamasoba D., Nasser H., Ito H., Zahradnik J., Wu J., Fujita S., Uriu K., Sasaki J., Tamura T., Suzuki R., Deguchi S., Plianchaisuk A., Yoshimatsu K., Kazuma Y., Mitoma S., Schreiber G., Asakura H., Nagashima M., Sadamasu K., Yoshimura K., Takaori-Kondo A.; Genotype to Phenotype Japan (G2P-Japan) Consortium; Ito J., Shirakawa K., Takayama K., Irie T., Hashiguchi T., Nakagawa S., Fukuhara T., Saito A., Ikeda T., Sato K.
J Virol. 2023 Oct 5:e0101123.
Pluripotent stem cell-based therapies and their path to the clinic
Takayama K.*, Yamanaka S.*
Stem Cell Reports, 2023 Aug 8;18(8):1547-48. (editorial)
Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
Tamura T., Yamasoba D., Oda Y., Ito J., Kamasaki T., Nao N., Hashimoto R., Fujioka Y., Suzuki R., Wang L., Ito H., Kashima Y., Kimura I., Kishimoto M., Tsuda M., Sawa H., Yoshimatsu K., Yamamoto Y., Nagamoto T., Kanamune J., Suzuki Y., Ohba Y.; Genotype to Phenotype Japan (G2P-Japan) Consortium; Yokota I.*, Matsuno K.*, Takayama K.*, Tanaka S.*, Sato K.*, Fukuhara T.*
Commun Biol. 2023 Jul 24;6(1):772.
Virological characterization of the 2022 outbreak-causing monkeypox virus using human keratinocytes and colon organoids
Watanabe Y., Kimura I., Hashimoto R., Sakamoto A., Yasuhara N., Yamamoto T.; Genotype to Phenotype Japan (G2P-Japan) Consortium; Sato K.*, Takayama K.*
J Med Virol. 2023 Jun;95(6):e28827.
Organ-on-a-chip models for elucidating the cellular biology of infectious diseases.
Yokoi F., Deguchi S., Takayama K.*
Biochim Biophys Acta Mol Cell Res. 2023 May 26:119504. (review)
Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants
Tamura T., Ito J., Uriu K., Zahradnik J., Kida I., Anraku Y., Nasser H., Shofa M., Oda Y., Lytras S., Nao N., Itakura Y., Deguchi S., Suzuki R., Wang L., Begum MM., Kita S., Yajima H., Sasaki J., Sasaki-Tabata K., Shimizu R., Tsuda M., Kosugi Y., Fujita S., Pan L., Sauter D., Yoshimatsu K., Suzuki S., Asakura H., Nagashima M., Sadamasu K., Yoshimura K., Yamamoto Y., Nagamoto T., Schreiber G., Maenaka K.; Genotype to Phenotype Japan (G2P-Japan) Consortium; Hashiguchi T., Ikeda T., Fukuhara T., Saito A., Tanaka S.*, Matsuno K.*, Takayama K.*, Sato K.*
Nat Commun. 2023 May 16;14(1):2800.
Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant
Ito J., Suzuki R., Uriu K., Itakura Y., Zahradnik J., Kimura KT., Deguchi S., Wang L., Lytras S., Tamura T., Kida I., Nasser H., Shofa M., Begum MM., Tsuda M., Oda Y., Suzuki T., Sasaki J., Sasaki-Tabata K., Fujita S., Yoshimatsu K., Ito H., Nao N., Asakura H., Nagashima M., Sadamasu K., Yoshimura K., Yamamoto Y., Nagamoto T., Kuramochi J., Schreiber G.; Genotype to Phenotype Japan (G2P-Japan) Consortium; Saito A., Matsuno K., Takayama K., Hashiguchi T.*, Tanaka S.*, Fukuhara T.*, Ikeda T.*, Sato K.*
Nat Commun. 2023 May 11;14(1):2671.
Evaluation of broad anti-coronavirus activity of autophagy-related compounds using human airway organoids
Hashimoto R., Tamura T., Watanabe Y., Sakamoto A., Yasuhara N., Ito H., Nakano M., Fuse H., Ohta A., Noda T., Matsumura Y., Nagao M., Yamamoto T., Fukuhara T.*, Takayama K.*
Mol Pharm. 2023 Apr 3;20(4):2276-2287.
Elucidation of the liver pathophysiology of COVID-19 patients using liver-on-a-chips
Deguchi S., Kosugi K., Hashimoto R., Sakamoto A., Yamamoto M., Krol RP., Gee P., Negoro R., Noda T., Yamamoto T., Torisawa YS., Nagao M., Takayama K.*
PNAS Nexus, 2023 Mar 7;2(3):pgad029.
Design of a chimeric ACE-2/Fc-silent fusion protein with ultrahigh affinity and neutralizing capacity for SARS-CoV-2 variants
Bodie NM., Hashimoto R., Connolly D., Chu J., Takayama K.*, Uhal BD.*
Antib Ther. 2023 Jan 20;6(1):59-74.
Upregulation of Robo4 expression by SMAD signaling suppresses vascular permeability and mortality in endotoxemia and COVID-19 models
Morita M., Yoneda A., Tokunoh N., Masaki T., Shirakura K., Kinoshita M., Hashimoto R., Shigesada N., Takahashi J., Tachibana M., Tanaka S., Obana M., Hino N., Ikawa M., Tsujikawa K., Ono C., Matsuura Y., Kidoya H., Takakura N., Kubota Y., Doi T., Takayama K., Yoshioka Y., Fujio Y., Okada Y.
Proc Natl Acad Sci U S A. 2023 Jan 17;120(3):e2213317120.
Gene therapy for neuropsychiatric disorders: potential targets and tools
Shahcheraghi SH., Ayatollahi J., Lotfi M., Aljabali AAA., Al-Zoubi MS., Panda PK., Mishra V., Satija S., Charbe NB., Serrano-Aroca Á., Bahar B., Takayama K., Goyal R., Bhatia A., Almutary AG., Alnuqaydan AM., Mishra Y., Negi P., Courtney A., McCarron PA., Bakshi HA., Tambuwala MM.
CNS Neurol Disord Drug Targets, 2023;22(1):51-65. (review)
State-of-the-art liver disease research using liver-on-a-chip
Deguchi S, Takayama K.*
Inflamm Regen. 2022 Dec 9;42(1):62. (review)
Non-uniform aspects of the SARS-CoV-2 intraspecies evolution reopen question of its origin
Hassan SS., Kodakandla V., Redwan EM., Lundstrom K., Choudhury PP., Serrano-Aroca Á., Azad GK., Aljabali AAA., Palu G., El-Aziz TMA., Barh D., Uhal BD., Adadi P., Takayama K., Bazan NG., Tambuwala M., Sherchan SP., Lal A., Chauhan G., Baetas-da-Cruz W., Uversky VN.
Int J Biol Macromol. 2022 Dec 1;222(Pt A):972-993.
Exocyst complex component 2 is a potential host factor for SARS-CoV-2 infection
Yi R., Hashimoto R., Sakamoto A., Matsumura Y., Nagao M., Takahashi K., Takayama K.*
iScience, 2022 Nov 18;25(11):105427.
Virological characteristics of the SARS-CoV-2 Omicron BA.2.75
Saito A., Tamura T., Zahradnik J., Deguchi S., Tabata K., Anraku Y., Kimura I., Ito J., Yamasoba D., Nasser H., Toyoda M., Nagata K., Uriu K., Kosugi Y., Fujita S., Shofa M., Monira Begum M., Shimizu R., Oda Y., Suzuki R., Ito H., Nao N., Wang L., Tsuda M., Yoshimatsu K., Kuramochi J., Kita S., Sasaki-Tabata K., Fukuhara H., Maenaka K., Yamamoto Y., Nagamoto T., Asakura H., Nagashima M., Sadamasu K., Yoshimura K., Ueno T., Schreiber G., Takaori-Kondo A., Genotype to Phenotype Japan (G2P-Japan) Consortium, Shirakawa K., Sawa H., Irie T., Hashiguchi T., Takayama K., Matsuno K., Tanaka S., Ikeda T., Fukuhara T., Sato K.
Cell Host Microbe. 2022 Nov 9;30(11):1540-1555.e15.
Application of perfluoropolyether elastomers in microfluidic drug metabolism assays
Wang M., Tsuda M., Deguchi S., Higuchi Y., So K., Torisawa YS., Takayama K., Yamashita F.
Int J Pharm. 2022 Nov 5;627:122253.
SARS-CoV-2 disrupts respiratory vascular barriers by suppressing Claudin-5 expression
Hashimoto R., Takahashi J., Shirakura K., Funatsu R., Kosugi K., Deguchi S., Yamamoto M., Tsunoda Y., Morita M., Muraoka K., Tanaka M., Kanbara T., Tanaka S., Tamiya S., Tokunoh N., Kawai A., Ikawa M., Ono C., Tachibana K., Kondoh M., Obana M., Matsuura Y., Ohsumi A., Noda T., Yamamoto T., Yoshioka Y., Torisawa YS., Date H., Fujio Y., Nagao M., Takayama K.*, Okada Y.*
Sci Adv. 2022 Sep 23;8(38):eabo6783.
Intestinal permeability of drugs in Caco-2 cells cultured in microfluidic devices
Sasaki Y., Tatsuoka H., Tsuda M., Sumi T., Eguchi Y., So K., Higuchi Y., Takayama K., Torisawa Y., Yamashita F.
Biol. Pharm. Bull., 2022;45(9):1246-1253.
Cell response analysis in SARS-CoV-2 infected bronchial organoids
Sano E., Suzuki T., Hashimoto R., Itoh Y., Sakamoto A., Sakai Y., Saito A., Okuzaki D., Motooka D., Muramoto Y., Noda T., Takasaki T., Sakuragi JI., Minami S., Kobayashi T., Yamamoto T., Matsumura Y., Nagao M., Okamoto T.*, Takayama K.*
Commun Biol. 2022 May 30;5(1):516.
Generation of HepG2 cells with high expression of multiple drug-metabolizing enzymes for drug discovery research using a PITCh system
Negoro R., Tasaka M., Deguchi S., Takayama K., Fujita T.
Cells. 2022 May 18;11(10):1677.
Would new SARS-CoV-2 variants change the war against COVID-19?
Redwan EM., Elrashdy F., Aljabali AAA., Baetas-da-Cruz W., Barh D., Brufsky AM., Hassan SS., Lundstrom K., Serrano-Aroca Á., Takayama K., Tambuwala MM., Uhal BD., Uversky VN.
Epidemiologia (Basel). 2022 Apr 29;3(2):229-237. (communication)
Biocompatible films of calcium alginate inactivate enveloped viruses such as SARS-CoV-2
Cano-Vicent A., Hashimoto R., Takayama K.*, Serrano-Aroca Á.*
Polymers (Basel). 2022 Apr 6;14(7):1483.
An issue of concern: Unique truncated ORF8 protein variants of SARS-CoV-2
Hassan SS., Kodakandla V., Redwan EM., Lundstrom K., Pal Choudhury P., Abd El-Aziz TM., Takayama K., Kandimalla R., Lal A., Serrano-Aroca Á., Azad GK., Aljabali AAA., Palù G., Chauhan G., Adadi P., Tambuwala M., Brufsky AM., Baetas-da-Cruz W., Barh D., Azevedo V., Bazan NG., Andrade BS., Santana Silva RJ., Uversky VN.
PeerJ, 2022 Mar 21;10:e13136.
The importance of accessory protein variants in the pathogenicity of SARS-CoV-2
Hassan SS., Choudhury PP., Dayhoff GW., Aljabali AAA., Uhal BD., Lundstrom K., Rezaei N., Pizzol D., Adadi P., Lal A., Soares A., Abd El-Aziz TM., Brufsky AM., Azad GK., Sherchan SP., Baetas-da-Cruz W., Takayama K., Serrano-Aroca Ã., Chauhan G., Palu G., Mishra YK., Barh D., Santana Silva RJ., Andrade BS., Azevedo V., Góes-Neto A., Bazan NG., Redwan EM., Tambuwala M., Uversky VN.
Arch Biochem Biophys. 2022 Mar 15;717:109124.
Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening
Tanaka T., Saito A., Suzuki T., Miyamoto Y., Takayama K., Okamoto T., Moriishi K.
Antiviral Res. 2022 Mar 7;199:105268.
Periodically aperiodic pattern of SARS-CoV-2 mutations underpins the uncertainty of its origin and evolution
Hassan SS., Basu P., Redwan EM., Lundstrom K., Choudhury PP., Serrano-Aroca Á., Azad GK., Aljabali AAA., Palu G., Abd El-Aziz TM., Barh D., Uhal BD., Adadi P., Takayama K., Bazan NG., Tambuwala MM., Lal A., Chauhan G., Baetas-da-Cruz W., Sherchan SP., Uversky VN.
Environ Res. 2022 Mar;204(Pt B):112092.
SARS-CoV-2 infection triggers paracrine senescence and leads to a sustained senescence-associated inflammatory response
Tsuji S., Minami S., Hashimoto R., Konishi Y., Suzuki T., Kondo T., Sasai M., Torii S., Ono C., Shichinohe S., Sato S., Wakita M., Okumura S., Nakano S., Matsudaira T., Matsudaira T., Matsumoto T., Kawamoto S., Yamamoto M., Watanabe T., Matsuura Y., Takayama K., Kobayashi T., Okamoto T., Hara E.
Nature Aging, 2022 Jan 25;2:115–124.
Emergence of unique SARS-CoV-2 ORF10 variants and their impact on protein structure and function
Hassan SS., Lundstrom K., Serrano-Aroca Á., Adadi P., Aljabali AAA., Redwan EM., Lal A., Kandimalla R., El-Aziz TMA., Pal Choudhury P., Azad GK., Sherchan SP., Chauhan G., Tambuwala M., Takayama K., Barh D., Palu G., Basu P., Uversky VN.
Int J Biol Macromol. 2022 Jan 1;194:128-143.
Therapeutic potential of cannabinoids on tumor microenvironment: a molecular switch in neoplasia transformation
Bakshi HA., Faruck HL., Ravesh Z., Ansari P., Hannan JMA., Hashimoto R., Takayama K., Farzand R., Nasef MM., Mensah A., Aljabali AAA., Mishra V., Charbe NB., Goyal R., Negi P., Serrano-Aroca Á., Bahar B., El-Tanani M., Courtenay AJ., McCarron P., Jack IG., Tambuwala MM.
Integr Cancer Ther. 2022 Jan-Dec;21:15347354221096766. (review)
Protective face masks: current status and future trends
Tuñón-Molina A., Takayama K., Redwan EM., Uversky VN., Andrés J., Serrano-Aroca Á.
ACS Appl Mater Interfaces. 2021 Dec 8;13(48):56725-56751. (review)
Dual inhibition of TMPRSS2 and Cathepsin B prevents SARS-CoV-2 infection in iPS cells
Hashimoto R., Sakamoto A., Deguchi S., Yi R., Sano E., Hotta A., Takahashi K., Yamanaka S., Takayama K.*
Mol Ther Nucleic Acids. 2021 Dec 3;26:1107-1114.
Clinical utility of novel biosensing platform: Diagnosis of coronavirus SARS-CoV-2 at point of care
Aljabali AAA., Pal K., Serrano-Aroca A., Takayama K., Dua K., Tambuwala MM.
Mater Lett. 2021 Dec 1;304:130612. (review)
Implications derived from S-protein variants of SARS-CoV-2 from six continents
Hassan SS., Lundstrom K., Barh D., Silva RJS., Andrade BS., Azevedo V., Choudhury PP., Palu G., Uhal BD., Kandimalla R., Seyran M., Lal A., Sherchan SP., Azad GK., Aljabali AAA., Brufsky AM., Serrano-Aroca Á., Adadi P., Abd El-Aziz TM., Redwan EM., Takayama K., Rezaei N., Tambuwala M., Uversky VN.
Int J Biol Macromol., 2021 Nov 30;191:934-955.
Non-woven infection prevention fabrics coated with biobased cranberry extracts inactivates enveloped viruses such as SARS-CoV-2 and multidrug-resistant bacteria
Takayama K., Tuñón-Molina A., Cano-Vicent A., Muramoto Y., Noda T., Aparicio-Collado JL., Sabater I Serra R., Martí M., Serrano-Aroca Á.
Int J Mol Sci., 2021 Nov 24;22(23):12719.
Autoimmunity roots of the thrombotic events after COVID-19 vaccination
Elrashdy F., Tambuwala MM., Hassan SS., Adadi P., Seyran M., Abd El-Aziz TM., Rezaei N., Lal A., Aljabali AAA., Kandimalla R., Bazan NG., Azad GK., Sherchan SP., Choudhury PP., Serrano-Aroca Á., Takayama K., Chauhan G., Pizzol D., Barh D., Panda PK., Mishra YK., Palù G., Lundstrom K., Redwan EM., Uversky VN.
Autoimmun Rev. 2021 Nov;20(11):102941. (review)
SARS-CoV-2 research using human pluripotent stem cells and organoids
Deguchi S., Serrano-Aroca Á., Tambuwala MM., Uhal BD., Brufsky AM., Takayama K.*
Stem Cells Transl Med. 2021 Nov;10(11):1491-1499. (review)
Targeting LIN28: a new hope in prostate cancer theranostics
Shrivastava G., Aljabali AA., Shahcheraghi SH., Lotfi M., Shastri MD., Shukla SD., Chellappan DK., Jha NK., Anand K., Dureja H., Pabari RM., Mishra V., Almutary AG., Alnuqaydan AM., Charbe N., Prasher P., Negi P., Goyal R., Dua K., Gupta G., Serrano-Aroca Á., Bahar B., Barh D., Panda PK., Takayama K., Lundstorm K., McCarron P., Bakshi H., Tambuwala MM.
Future Oncol. 2021 Oct;17(29):3873-3880. (review)
The mechanism behind flaring/triggering of autoimmunity disorders associated with COVID-19
Redwan EM., Alghamdi MF., El-Aziz TMA., Adadi P., Aljabali AAA., Attrish D., Azad GK., Baetas-da-Cruz W., Barh D., Bazan NG., Brufsky AM., Chauhan G., Hassan SKS., Kandimalla R., Lal A., Lundstrom K., Mishra YK., Choudhury PP., Palù G., Panda PK., Pizzol D., Rezaei N., Serrano-Aroca Á., Sherchan SP., Seyran M., Takayama K., Tambuwala MM., Uhal BD., Uversky VN.
Autoimmun Rev., 2021 Oct;20(10):102909. (review)
Potential molecular mechanisms of rare anti-tumor immune response by SARS-CoV-2 in isolated cases of lymphomas
Barh D., Tiwari S., Gabriel Rodrigues Gomes L., Weener ME., Alzahrani KJ., Alsharif KF., Aljabali AAA., Tambuwala MM., Lundstrom K., Hassan SS., Serrano-Aroca Á., Takayama K., Ghosh P., Redwan EM., Silva Andrade B., Soares SC., Azevedo V., Uversky VN.
Viruses, 2021 Sep 25;13(10):1927. (review)
Tetrafluoroethylene-propylene elastomer-based liver-on-a-chip resistant to drug absorption
Sano E., Deguchi S., Matsuoka N., Tsuda M., Wang M., Kosugi K., Mori C., Yagi K., Wada A., Yamasaki S., Kawai T., Yodogawa M., Mizuguchi H., Nakazawa N., Yamashita F., Torisawa YS.*, Takayama K.*
ACS Omega, 2021 Sep 15;6(38):24859-24865.
Antiviral face mask functionalized with solidified hand soap: low-cost infection prevention clothing against enveloped viruses such as SARS-CoV-2
Cano-Vicent A., Tuñón-Molina A., Martí M., Muramoto Y., Noda T., Takayama K.*, Serrano-Aroca A.*
ACS Omega, 2021 Sep 2;6(36):23495-23503.
Antimicrobial face shield: next generation of facial protective equipment against SARS-CoV-2 and multidrug-resistant bacteria
Tuñón-Molina A., Martí M., Muramoto Y., Noda T., Takayama K.*, and Serrano-Aroca A.*
Int J Mol Sci. 2021 Sep 1;22(17):9518.
The structural basis of accelerated host cell entry by SARS-CoV-2
Seyran M., Takayama K., Lal A., Uversky V., Lundstrom K, Palù G., Sherchan S., Attrish D., Rezaei N., Aljabali A., Ghosh S., Pizzol D., Chauhan G., Adadi O., El-Aziz T., Soares A., Kandimalla R., Tambuwala M., Hassan S., Azad G., ChoudhuryP., Baetas-da-Cruz W., Serrano-Aroca A., Brufsky A., Uhal B.
FEBS J., 2021 Sep;288(17):5010-5020. (Structural Snapshot)
Usability of polydimethylsiloxane-based microfluidic devices in pharmaceutical research using human hepatocytes
Deguchi S., Tsuda M., Kosugi K., Sakamoto A., Mimura N., Negoro R., Sano E., Nobe T., Maeda K., Kusuhara H., Mizuguchi H., Yamashita F., Torisawa YS.*, Takayama K.*
ACS Biomater Sci Eng. 2021 Aug 9;7(8):3648-3657.
COVID-19 vaccines and thrombosis – roadblock or dead-end street?
Lundstrom K., Barh D., Uhal B., Takayama K., Aljabali A., El-Aziz T., Lal A., Redwan E., Adadi P., Chauhan G., Sherchan S., Azad G., Rezaei N., Serrano-Aroca A., Bazan N., Hassan S., Panda P., Choudhury P., Pizzol D., Kandimalla R., Baetas-da-Cruz W., Mishra Y., Palu G., Brufsky A., Tambuwala M., Uversky V.
Biomolecules. 2021 Jul 13;11(7):1020. (review)
Notable sequence homology of the ORF10 protein introspects the architecture of SARS-CoV-2
Hassan SS., Attrish D., Ghosh S., Choudhury PP., Uversky VN., Aljabali AAA., Lundstrom K., Uhal BD., Rezaei N., Seyran M., Pizzol D., Adadi P., Soares A., Abd El-Aziz TM., Kandimalla R., Tambuwala MM., Azad GK., Sherchan SP., Baetas-da-Cruz W., Lal A., Palù G., Takayama K., Serrano-Aroca Á., Barh D., Brufsky AM.
Int J Biol Macromol. 2021 Jun 30;181:801-809.
A unique view of SARS-COV-2 through the lens of ORF8 protein
Hassan SS., Aljabali AAA., Panda PK., Ghosh S., Attrish D., Choudhury PP., Seyran M., Pizzol D., Adadi P., Abd El-Aziz TM., Soares A., Kandimalla R., Lundstrom K., Lal A., Azad GK., Uversky VN., Sherchan SP., Baetas-da-Cruz W., Uhal BD., Rezaei N., Chauhan G., Barh D., Redwan EM., Dayhoff GW., Bazan NG., Serrano-Aroca Á., El-Demerdash A., Mishra YK., Palu G., Takayama K., Brufsky AM., Tambuwala MM.
Comput Biol Med. 2021 Jun;133:104380.
Carbon-based nanomaterials: promising antiviral agents to combat COVID-19 in the microbial-resistant era
Serrano-Aroca Á., Takayama K., Tuñón-Molina A., Seyran M., Hassan SS., Pal Choudhury P., Uversky VN., Lundstrom K., Adadi P., Palù G., Aljabali AAA., Chauhan G., Kandimalla R., Tambuwala MM., Lal A., Abd El-Aziz TM., Sherchan S., Barh D., Redwan EM., Bazan NG., Mishra YK., Uhal BD., Brufsky A.
ACS Nano. 2021 May 25;15(5):8069-8086. (review)
Modeling SARS-CoV-2 infection and its individual differences with ACE2-expressing human iPS cells
Sano E., Deguchi S., Sakamoto A., Mimura N., Hirabayashi A., Muramoto Y., Noda T., Yamamoto T., Takayama K.*
iScience, 2021 May 21;24(5):102428.
Overview of key molecular and pharmacological targets for diabetes and associated diseases
Shahcheraghi SH., Aljabali AAA., Al Zoubi MS., Mishra V., Charbe NB., Haggag YA., Shrivastava G., Almutary AG., Alnuqaydan AM., Barh D., Dua K., Chellappan DK., Gupta G., Lotfi M., Serrano-Aroca Á., Bahar B., Mishra YK., Takayama K., Panda PK., Bakshi HA., Tambuwala MM.
Life Sci., 2021 May 18;278:119632. (review)
Protective face mask filter capable of inactivating SARS-CoV-2, and methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis
Martí M., Tuñón-Molina A., Aachmann FL., Muramoto Y., Noda T., Takayama K.*, Serrano-Aroca Á.*
Polymers (Basel). 2021 Jan 8;13(2):207.
Possible transmission flow of SARS-CoV-2 based on ACE2 features
Hassan SS., Ghosh S., Attrish D., Choudhury PP., Aljabali AAA., Uhal BD., Lundstrom K., Rezaei N., Uversky VN., Seyran M., Pizzol D., Adadi P., Soares A., El-Aziz TMA., Kandimalla R., Tambuwala MM., Azad GK., Sherchan SP., Baetas-da-Cruz W., Takayama K., Serrano-Aroca Á., Chauhan G., Palu G., Brufsky AM.
Molecules, 2020 Dec 13;25(24):5906.
Introductions to the community: early-career researchers in the time of COVID-19
Takayama K., Weaver LN., Lummertz da Rocha E., Lo Sardo V., Gehart H., Vu LP.
Cell Stem Cell. 2020 Dec 3;27(6):853-855. (Voices)
In vitro and animal models for SARS-CoV-2 research
Takayama K.*
Trends Pharmacol Sci., 2020 Aug;41(8):513-517. (Forum)
----- The followings are research achievements at Osaka University (FY2009-FY2020)-----
A general fluorescence off/on strategy for fluorogenic probes: Steric repulsion-induced twisted intramolecular charge transfer (sr-TICT)
Hanaoka K., Ikeno T., Iwaki S., Deguchi S., Takayama K., Mizuguchi H., Tao F., Kojima N., Ohno H., Sasaki E., Komatsu T., Ueno T., Maeda K., Kusuhara H., Urano Y.
Sci Adv. 2024 Feb 16;10(7):eadi8847.
Decellularized organ-derived scaffold is a promising carrier for human induced pluripotent stem cells-derived hepatocytes
Kojima H., Yagi H., Kushige H., Toba Y., Takayama K., Masuda S., Morisaku T., Tsuchida T., Kuroda K., Hirukawa K., Inui J., Nishi K., Nakano Y., Tanaka M., Hori S., Hasegawa Y., Abe Y., Kitago M., Adachi S., Tomi M., Matsuura K., Mizuguchi H., Kitagawa Y.
Cells, 2022 Apr 7;11(8):1258.
Generation of tetracycline-controllable CYP3A4-expressing Caco-2 cells by the piggyBac transposon system
Ichikawa M., Akamine H., Murata M., Ito S., Takayama K., Mizuguchi H.
Sci Rep., 2021 Jun 3;11(1):11670.
In vitro model for a drug assessment of cytochrome P450 family 3 subfamily a member 4 substrates using human induced pluripotent stem cells and genome editing technology
Deguchi S., Shintani T., Harada K., Okamoto T., Takemura A. Hirata K., Ito K., Takayama K.*, Mizuguchi H.*
Hepatol Commun. 2021 May 5;5(8):1385-1399.
Asymmetric profiles of infection and innate immunological responses in human iPS cell-derived small intestinal epithelial-like cell monolayers following infection with mammalian reovirus
Inoue C., Negoro R., Takayama K., Mizuguchi H., Sakurai F.
Virus Res., 2021 Apr 15;296:198334.
In vivo gene expression profile of human intestinal epithelial cells: from the viewpoint of drug metabolism and pharmacokinetics
Takayama K., Ito K., Matsui A., Yamashita T., Kawakami K., Hirayama D., Kishimoto W., Nakase H., Mizuguchi H.
Drug Metab Dispos., 2021 Mar;49(3):221-232.
Vinblastine treatment enhances the intestinal functions and decreases the undifferentiated cell contamination of human iPS cell-derived intestinal epithelial-like cells
Ichikawa M., Negoro R., Kawai K., Yamashita T., Takayama K., Mizuguchi H.
Mol Ther Methods Clin Dev., 2021 Jan 20;20:463-472.
Photoactivatable oncolytic adenovirus for optogenetic cancer therapy
Hagihara Y., Sakamoto A., Tokuda T., Yamashita T., Ikemoto S., Kimura A., Haruta M., Sasagawa K., Ohta J., Takayama K.*, Mizuguchi H.*
Cell Death Dis., 2020 Jul 23;11(7):570.
Establishment of MDR1/ABCB1-knockout human induced pluripotent stem cell line
Negoro R.1, Kawai K.1, Ichikawa M., Deguchi S., Takayama K.*, Mizuguchi H.*
Drug Metab Pharmacokinet., 2020 Jun;35(3):288-296.
Generation of human iPS cell-derived hepatocyte-like cells for cellular medicine
Deguchi S., Takayama K.*, Mizuguchi H.*
Biol Pharm Bull., 2020;43(4):608-615. (review)
Comparison of commercially available media for hepatic differentiation and hepatocyte maintenance
Toba Y., Deguchi S., Mimura N., Sakamoto A., Harada K., Hirata K., Takayama K.*, Mizuguchi H.*
PLoS One, 2020 Feb 27;15(2):e0229654.
Tolloid-like 1 negatively regulates hepatic differentiation of human induced pluripotent stem cells through transforming growth factor beta signaling
Kiso A.1, Toba Y.1, Tsutsumi S., Deguchi S., Igai K., Koshino S., Tanaka Y., Takayama K.*, Mizuguchi H.*
Hepatol Commun., 2020 Jan 2;4(2):255-267.
Establishment of SLC15A1/PEPT1-knockout human induced pluripotent stem cell line for intestinal drug absorption studies
Kawai K., Negoro R., Ichikawa M., Yamashita T., Deguchi S., Harada K., Hirata K., Takayama K.*, Mizuguchi H.*
Mol Ther Methods Clin Dev., 2019 Nov 21;17:49-57.
Generation of human iPS cell-derived intestinal epithelial cell monolayers by CDX2 transduction
Takayama K.1*, Negoro R.1, Yamashita T., Kawai K, Ichikawa M, Mori T, Nakatsu N, Harada K, Ito S, Yamada H, Yamaura Y, Hirata K, Ishida S, Mizuguchi H.*
Cell Mol Gastroenterol Hepatol., 2019 Jun 19;8(3):513-526.
Modeling of hepatic drug metabolism and responses in CYP2C19 poor metabolizer using genetically manipulated human iPS cells
Deguchi S., Yamashita T., Igai K., Harada K., Toba Y., Hirata K., Takayama K.*, Mizuguchi H.*
Drug Metab Dispos., 2019 Jun;47(6):632-638.
FGF signal is not required for hepatoblast differentiation of human iPS cells
Toba Y., Kiso A., Nakamae S., Sakurai F., Takayama K.*, Mizuguchi H.*
Sci Rep., 2019 Mar 6;9(1):3713.
Pharmaceutical research for inherited metabolic disorders of the liver using human induced pluripotent stem cell and genome editing technologies
Yamashita T., Takayama K.*, Hori M., Harada-Shiba M., Mizuguchi H.
Biol. Pharm. Bull., 2019;42(3):312-318. (review)
Efficient generation of small intestinal epithelial-like cells from human iPS cells for drug absorption and metabolism studies
Negoro R., Takayama K.*, Kawai K., Harada K., Sakurai F., Hirata K., Mizuguchi H.*
Stem Cell Reports, 2018 Dec 11;11(6):1539-1550.
Optimal human iPS cell culture method for efficient hepatic differentiation
Matoba N.1, Yamashita T.1, Takayama K.*, Sakurai F., Mizuguchi H.*
Differentiation, 2018 Sep 24;104:13-21.
Enrichment of high-functioning human iPS cell-derived hepatocyte-like cells for pharmaceutical research
Takayama K.*, Hagihara Y., Toba Y., Sekiguchi K., Sakurai F., Mizuguchi H*
Biomaterials, 2018 Apr;161:24-32.
Nanaomycin A treatment promotes hepatoblast differentiation from human iPS cells
Nakamae S.1, Toba Y.1, Takayama K.*, Sakurai F., Mizuguchi H*
Stem Cells Dev., 2018 Mar 15;27(6):405-414.
Human iPS cell-based liver-like tissue engineering at extrahepatic sites in mice as a new cell therapy for Hemophilia B
Okamoto R.1, Takayama K.1, Akita N.1, Nagamoto Y., Hosokawa D., Iizuka S., Sakurai F., Suemizu H., Ohashi K., Mizuguchi H.
Cell Transplant., 2018 Feb;27(2):299-309.
Billion-scale production of hepatocyte-like cells from human induced pluripotent stem cells
Yamashita T., Takayama K.*, Sakurai F., Mizuguchi H*.
Biochem Biophys Res Commun., 2018 Feb 19;496(4):1269-1275.
Generation of optogenetically modified adenovirus vector for spatiotemporally controllable gene therapy
Takayama K.*, Mizuguchi H*.
ACS Chem Biol., 2018 Feb 16;13(2):449-454.
Overexpression of miR-27b negatively regulates expression of pluripotency-associated genes and hepatic differentiation in human induced pluripotent stem cells
Lim J., Sakai E., Takayama K., Sakurai F., Mizuguchi H.
Stem Cell Research & Therapeutics, 2018; 2(1): 88-97.
Direct conversion of human fibroblasts into hepatocyte-like cells by ATF5, PROX1, FOXA2, FOXA3, and HNF4A transduction
Nakamori D.1, Akamine H.1, Takayama K.1, Sakurai F., Mizuguchi H.
Sci Rep., 2017 Nov 30;7(1):16675.
Hepatitis C virus-induced innate immune responses in human iPS cell-derived hepatocyte-like cells
Sakurai F., Kunito T., Takayama K., Hashimoto R., Tachibana M., Sakamoto N., Wakita T., Mizuguchi H.
Virus Res., 2017 Oct 15;242:7-15.
Generation of safe and therapeutically effective human induced pluripotent stem cell-derived hepatocyte-like cells for regenerative medicine
Takayama K.1, Akita N.1, Mimura N., Akahira R., Taniguchi Y., Ikeda M., Sakurai F., Ohara O., Morio T., Sekiguchi K., Mizuguchi H.
Hepatol Commun., 2017 Oct 12;1(10):1058-1069.
Inhibition of CRISPR/Cas9-mediated genome engineering by a Type I interferon-induced reduction in guide RNA expression
Machitani M., Sakurai F., Wakabayashi K., Nakatani K., Takayama K., Tachibana M., Mizuguchi H.
Biol Pharm Bull, 2017;40(3):272-277.
Hepatocyte nuclear factor 4 alpha promotes definitive endoderm differentiation from human induced pluripotent stem cells
Hanawa M., Takayama K., Sakurai F., Tachibana M., Mizuguchi H.
Stem Cell Rev Rep., 2017 Aug;13(4):542-551.
Human ESC/iPSC-derived hepatocyte-like cells achieve zone-specific hepatic properties by modulation of WNT signaling
Mitani S.1, Takayama K.1, Nagamoto Y., Imagawa K., Sakurai F., Tachibana M., Sumazaki R., Mizuguchi H.
Mol Ther., 2017 Jun 7;25(6):1420-1433.
Highly efficient biallelic genome editing of human ES/iPS cells using a CRISPR/Cas9 or TALEN system
Takayama K., Igai K., Hagihara Y., Hashimoto R., Hanawa M., Sakuma T., Tachibana M., Sakurai F., Yamamoto T., Mizuguchi H.
Nucleic Acids Res., 2017 May 19;45(9):5198-5207.
Human induced-pluripotent stem cell-derived hepatocyte-like cells as an in vitro model of human hepatitis B virus infection
Sakurai F., Mitani S., Yamamoto T., Takayama K., Tachibana M., Watashi K., Wakita T., Iijima S., Tanaka Y., Mizuguchi H.
Sci Rep., 2017 Apr 4;7:45698.
Isolation and expansion of human pluripotent stem cell-derived hepatic progenitor cells by growth factor defined serum-free culture conditions
Fukuda T., Takayama K., Hirata M., Liu Y., Yanagihara K., Suga M., Mizuguchi H., Furue M.
Exp Cell Res., 2017 Mar 15;352(2):333-345.
Generation of a bile salt export pump deficiency model using patient-specific induced pluripotent stem cell-derived hepatocyte-like cells
Imagawa K. 1, Takayama K. 1, Isoyama S., Tanikawa K., Shinkai M., Harada K., Tachibana M., Sakurai F., Noguchi E., Hirata K., Kage M., Kawabata K., Sumazaki R., Mizuguchi H.
Sci Rep., 2017 Feb 2;7:41806.
Generation of human pluripotent stem cell-derived hepatocyte-like cells for drug toxicity screening
Takayama K.*, Mizuguchi H*.
Drug Metab Pharmacokinet., 2017 Feb;32(1):12-20. (review)
Prediction of differentiation tendency toward hepatocytes from gene expression in undifferentiated human pluripotent stem cells
Yanagihara K., Liu Y., Kanie K., Takayama K., Kokunugi M., Hirata M., Fukuda T., Suga M., Nikawa H., Mizuguchi H., Kato R., Furue M.
Stem Cells Dev., 2016 Dec 15;25(24):1884-1897.
Laminin 411 and 511 promote the cholangiocyte differentiation of human induced pluripotent stem cells
Takayama K.1, Mitani S.1, Nagamoto Y., Sakurai F., Tachibana M., Taniguchi Y., Sekiguchi K., Mizuguchi H.
Biochem Biophys Res Commun., 2016 May 20;474(1):91-6.
Transplantation of a human iPSC-derived hepatocyte sheet increases survival in mice with acute liver failure
Nagamoto Y., Takayama K., Ohashi K., Okamoto R., Sakurai F., Tachibana M., Kawabata K., Mizuguchi M.
J Hepatol., 2016 May;64(5):1068-1075.
Modeling of drug-mediated CYP3A4 induction by using human iPS cell-derived enterocyte-like cells
Negoro R.1, Takayama K.1, Nagamoto Y, Sakurai F., Tachibana M, Mizuguchi H.
Biochem Biophys Res Commun., 2016 Apr 15;472(4):631-636.
Hepatic maturation of human iPS cell-derived hepatocyte-like cells by ATF5, c/EBPα, and PROX1 transduction
Nakamori D.1, Takayama K.1, Nagamoto Y., Mitani S., Sakurai F., Tachibana M., Mizuguchi H.
Biochem Biophys Res Commun., 2016 Jan 15;469(3):424-429.
Generation of enterocyte-like cells from human induced pluripotent stem cells for drug absorption and metabolism studies in human small intestine
Ozawa T.1, Takayama K.1, Okamoto R., Negoro R., Sakurai F., Tachibana M., Kawabata K., Mizuguchi H.
Sci Rep., 2015 Nov 12;5:16479.
Generation of brain microvascular endothelial-like cells from human induced pluripotent stem cells by co-culture with C6 glioma cells
Minami H., Tashiro K., Okada A., Hirata N., Yamaguchi T., Takayama K., Mizuguchi H., Kawabata K.
PLoS One, 2015 Jun 10; 10(6): e0128890.
Expression of coxsackievirus and adenovirus receptor separates hematopoietic and cardiac progenitor cells in Flk1-expressing mesoderm
Tashiro K., Hirata N., Okada A., Yamaguchi T., Takayama K., Mizuguchi H., Kawabata K.
STEM CELL Transl Med., 2015 May;4(5):424-36.
Efficient engraftment of human induced pluripotent stem cell-derived hepatocyte-like cells in uPA/SCID mice by overexpression of FNK, a Bcl-xL mutant gene
Nagamoto Y., Takayama K., Tashiro K., Tateno C., Sakurai F., Tachibana M., Kawabata K., Ikeda K., Tanaka Y., Mizuguchi H.
Cell Transplant., 2015;24(6):1127-38.
Prediction of interindividual differences in hepatic functions and drug sensitivity by using human iPS-derived hepatocytes
Takayama K., Morisaki Y., Kuno S., Nagamoto Y., Harada K., Furukawa N., Ohtaka M., Nishimura K., Imagawa K., Sakurai F., Tachibana M., Sumazaki R., Noguchi E., Nakanishi M., Hirata K., Kawabata K., Mizuguchi H.
Proc Natl Acad Sci U S A., 2014 Nov 25;111(47):16772-7.
HHEX promotes hepatic-lineage specification through the negative regulation of eomesodermin
Watanabe H.1, Takayama K.1, Inamura M., Tachibana M., Mimura N., Katayama K., Tashiro K., Nagamoto Y., Sakurai F., Kawabata K., Furue MK., Mizuguchi H.
PLoS One, 2014 Mar 20;9(3):e90791.
CCAAT/enhancer binding protein-mediated regulation of TGFβ receptor 2 expression determines the hepatoblast fate decision
Takayama K., Kawabata K., Nagamoto Y., Inamura M., Ohashi K., Okuno H., Yamaguchi T., Tashiro K., Sakurai F., Hayakawa T., Okano T., Furue MK., Mizuguchi H.
Development, 2014 Jan;141(1):91-100.
Long-term self-renewal of human ES/iPS-derived hepatoblast-like cells on human laminin 111-coated dishes
Takayama K., Nagamoto Y., Mimura N., Tashiro K., Sakurai F., Tachibana M., Hayakawa T., Kawabata K., Mizuguchi H.
Stem Cell Reports, 2013 Oct 3;1(4):322-35.
3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing
Takayama K., Kawabata K., Nagamoto Y., Kishimoto K., Tashiro K., Sakurai F., Tachibana M., Kanda K., Hayakawa T., Furue MK., Mizuguchi H.
Biomaterials, 2013 Feb;34(7):1781-9.
Generation of metabolically functioning hepatocytes from human pluripotent stem cells by FOXA2 and HNF1α transduction
Takayama K., Inamura M., Kawabata K., Sugawara M., Kikuchi K., Higuchi M., Nagamoto Y., Watanabe H., Tashiro K., Sakurai F., Hayakawa T., Furue MK., Mizuguchi H.
J Hepatol., 2012 Sep;57(3):628-36.
The promotion of hepatic maturation of human pluripotent stem cells in 3D co-culture using type I collagen and Swiss 3T3 cell sheets
Nagamoto Y., Tashiro K., Takayama K., Ohashi K., Kawabata K., Sakurai F., Tachibana M., Hayakawa T., Hayakawa H., Furue MK., Mizuguchi H.
Biomaterials, 2012 Jun;33(18):4526-34.
Endodermal and hepatic differentiation from human embryonic stem cells and human induced pluripotent stem cells
Kawabata K., Takayama K., Nagamoto Y., Saldon M.S., Higuchi M., Mizuguchi H.
J Stem Cell Res Ther., 2012 S10:002. doi: 10.4172/2157-7633.S10-002 (review)
Efficient generation of functional hepatocytes from human embryonic stem cells and induced pluripotent stem cells by HNF4α transduction
Takayama K., Inamura M., Kawabata K., Katayama K., Higuchi M., Tashiro K., Nonaka A., Sakurai F., Hayakawa T., Furue MK., Mizuguchi H.
Mol Ther., 2012 Jan;20(1):127-37.
Use of human hepatocyte-like cells derived from induced pluripotent stem cells as a model for hepatocytes in hepatitis C virus infection
Yoshida T.1, Takayama K.1, Kondoh M., Sakurai F., Tani H., Sakamoto N., Matsuura Y., Mizuguchi H., Yagi K.
Biochem Biophys Res Commun., 2011 Dec 9;416(1-2):119-24.
Efficient and directive generation of two distinct endoderm lineages from human ESCs and iPSCs by differentiation stage-specific SOX17 transduction
Takayama K., Inamura M., Kawabata K., Tashiro K., Katayama K., Hayakawa T., Furue MK., Mizuguchi H.
PLoS One, 2011;6(7):e21780.
Efficient generation of hepatoblasts from human ES cells and iPS cells by transient overexpression of homeobox gene HEX
Inamura M., Kawabata K., Takayama K., Tashiro K., Sakurai F., Katayama K., Toyoda M., Akutsu H., Miyagawa Y., Okita H., Kiyokawa N., Umezawa A., Hayakawa T., Furue MK., Mizuguchi H.
Mol Ther., 2011 Feb;19(2):400-7.
Adenovirus vector-mediated efficient transduction into human embryonic and induced pluripotent stem cells
Tashiro K., Kawabata K., Inamura M., Takayama K., Furukawa N., Sakurai F., Katayama K., Hayakawa H., Furue MK., Mizuguchi H.
Cell Reprogram., 2010 Oct;12(5):501-7.